Using bone marrow cells to treat premature ovarian insufficiency
Treatment of Premature Ovarian Insufficiency Using Autologous Bone Marrow Concentrates Through Transvaginal Approach Under Ultrasound Guidance
This study is testing whether using bone marrow cells can help women with premature ovarian insufficiency regain ovarian function and improve their hormone levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 30 Years to 60 Years |
| Sex | Female |
| Sponsor | Global Stem Cell Center, Baghdad Industry-sponsored |
| Locations | 1 site (Baghdad) |
| Trial ID | NCT06302543 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to treat premature ovarian insufficiency (POI) by administering autologous bone marrow-derived mononuclear cells both systematically and locally to the ovaries under ultrasound guidance. The study will evaluate the effectiveness of this approach through hormonal studies and ultrasound assessments to monitor ovarian follicle development. POI is characterized by early loss of ovarian function, and the trial seeks to provide an alternative treatment option without the need for oocyte donation. The use of regenerative medicine techniques, such as stem cell therapy, represents a novel approach to addressing this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are women under 40 years old diagnosed with premature ovarian insufficiency who have not responded to hormonal therapy.
Not a fit: Patients with solid or hematological malignancies or those with bleeding disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could restore ovarian function and improve hormonal balance in patients with premature ovarian insufficiency.
How similar studies have performed: While few cases have been reported using autologous stem cells for treating POI, this approach remains largely novel and untested on a larger scale.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. clinical diagnosis of premature Ovarian insufficiency. 2. ineffective hormonal therapy. 3. biochemical evidence of high gonadotropins. Exclusion criteria: 1. solid or hematological malignancies. 2. bleeding disorders. 3. rejection of the procedure.
Where this trial is running
Baghdad
- Ministry of Health — Baghdad, Iraq (Recruiting)
Study contacts
- Study coordinator: abdulmajeed hammadi, MD
- Email: majeed51578@yahoo.co.uk
- Phone: +9647902268105
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.